D013 clinical trials
How each study uses D013 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses D013 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mgCompletedPhase 1Chong Kun Dang PharmaceuticalNCT05698043Written as D013, D326, D337
- Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-386 in Healthy Volunteers Under Fasting ConditionsCompletedPhase 1Chong Kun Dang PharmaceuticalNCT05552495Written as D013, D326, D337
- A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80/20/10mgCompletedPhase 1Chong Kun Dang PharmaceuticalNCT05245084Written as D013, D326, D337
- A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2) 80/20/10mgCompletedPhase 1Chong Kun Dang PharmaceuticalNCT04987970Written as D013, D326, D337
- Clinical Trial to Evaluate the Efficacy and Safety of CKD-386CompletedPhase 3Chong Kun Dang PharmaceuticalNCT04312698Written as D013, D326, D337
- A Study to Investigate Drug Interaction Between D326, D337, and D013 in Healthy Male SubjectsCompletedPhase 1Chong Kun Dang PharmaceuticalNCT03609606Written as D013